MORF · Morphic Therapeutic
Acquired Company
Eli Lilly and Company completed the acquisition of Morphic Holding, Inc. and Morphic’s common stock will be delisted from Nasdaq.
Morphic Therapeutic is a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. In collaboration with AbbVie, Janssen, and Schrödinger, Morphic is advancing its pipeline and discovery activities using its proprietary MInT technology platform which leverages Morphic's unique understanding of integrin structure and biology.
Market Cap
N/A
52 Wk Range
N/A - N/A
Previous Close
$56.99
Open
$56.99
Volume
400
Day Range
$56.99 - $56.99
Enterprise Value
N/A
Cash
N/A
Avg Qtr Burn
N/A
Insider Ownership
17.13%
Institutional Own.
91.02%
Qtr Updated
Jun 30th 2024
